Andrew D Wiese1, Marie R Griffin1,2,3, William Schaffner1,2, C Michael Stein2, Robert A Greevy3,4, Edward F Mitchel1, Carlos G Grijalva1,3. 1. Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Mid-South Geriatric Research Education and Clinical Center, VA Tennessee Valley Health Care System, Nashville, Tennessee. 4. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
BACKGROUND: Although evidence from animal and human studies indicates opioid analgesics increase susceptibility to infections, it is unclear whether the risk varies by specific opioid. We compared the risk of serious infection among patients initiating long-acting opioid analgesics with and without previously reported immunosuppressive properties. METHODS: We conducted a retrospective cohort study of Tennessee Medicaid enrollees age ≥18 years initiating long-acting opioids (1995-2015). Hospitalizations for serious infection were identified using validated coding algorithms. We used multivariable Poisson regression models to calculate adjusted incidence rate ratios (aIRR) and 95% confidence intervals (CI) to compare the infection risk among patients using long-acting opioids with known immunosuppressive properties (morphine, fentanyl, methadone) to the infection risk among patients using long-acting opioids without known immunosuppressive properties (oxycodone, oxymorphone, tramadol) accounting for demographics, opioid dose, comorbidities and pain conditions, medication use, frailty indicators, and healthcare encounter history using exposure propensity scores. We further compared users of individual long-acting opioids to long-acting morphine users (considered the prototypical immunosuppressive opioid). RESULTS: Among the 61 240 patients initiating opioids with immunosuppressive properties and 22 811 patients initiating opioids without immunosuppressive properties, we identified 1906 serious infections. Nonimmunosuppressive opioid users had a lower rate of infections than immunosuppressive opioid users (aIRR:0.78 [CI: 0.66-0.91]). Among individual opioids, oxycodone users had a lower rate of infection than morphine users (aIRR:0.73 [CI: 0.60-0.89]). There were no significant differences in the infection risk between other opioids and morphine. CONCLUSION: The risk of serious infections among long-acting opioid users varies by opioid type. Providers should carefully consider the risk of serious infections when making pain management decisions.
BACKGROUND: Although evidence from animal and human studies indicates opioid analgesics increase susceptibility to infections, it is unclear whether the risk varies by specific opioid. We compared the risk of serious infection among patients initiating long-acting opioid analgesics with and without previously reported immunosuppressive properties. METHODS: We conducted a retrospective cohort study of Tennessee Medicaid enrollees age ≥18 years initiating long-acting opioids (1995-2015). Hospitalizations for serious infection were identified using validated coding algorithms. We used multivariable Poisson regression models to calculate adjusted incidence rate ratios (aIRR) and 95% confidence intervals (CI) to compare the infection risk among patients using long-acting opioids with known immunosuppressive properties (morphine, fentanyl, methadone) to the infection risk among patients using long-acting opioids without known immunosuppressive properties (oxycodone, oxymorphone, tramadol) accounting for demographics, opioid dose, comorbidities and pain conditions, medication use, frailty indicators, and healthcare encounter history using exposure propensity scores. We further compared users of individual long-acting opioids to long-acting morphine users (considered the prototypical immunosuppressive opioid). RESULTS: Among the 61 240 patients initiating opioids with immunosuppressive properties and 22 811 patients initiating opioids without immunosuppressive properties, we identified 1906 serious infections. Nonimmunosuppressive opioid users had a lower rate of infections than immunosuppressive opioid users (aIRR:0.78 [CI: 0.66-0.91]). Among individual opioids, oxycodone users had a lower rate of infection than morphine users (aIRR:0.73 [CI: 0.60-0.89]). There were no significant differences in the infection risk between other opioids and morphine. CONCLUSION: The risk of serious infections among long-acting opioid users varies by opioid type. Providers should carefully consider the risk of serious infections when making pain management decisions.
Authors: Wayne A Ray; C Michael Stein; James R Daugherty; Kathi Hall; Patrick G Arbogast; Marie R Griffin Journal: Lancet Date: 2002-10-05 Impact factor: 79.321
Authors: Carlos G Grijalva; Cecilia P Chung; C Michael Stein; Patricia S Gideon; Shannon M Dyer; Edward F Mitchel; Marie R Griffin Journal: Pharmacoepidemiol Drug Saf Date: 2008-09 Impact factor: 2.890
Authors: Daniel M Hartung; Luke Middleton; Dean G Haxby; Michele Koder; Kathy L Ketchum; Roger Chou Journal: Ann Pharmacother Date: 2007-05-15 Impact factor: 3.154
Authors: Salimah H Meghani; William E Rosa; Jesse Chittams; April Hazard Vallerand; Ting Bao; Jun J Mao Journal: Pain Manag Nurs Date: 2019-09-06 Impact factor: 1.929
Authors: Catherine Steffens; Minhee Sung; Lori A Bastian; E Jennifer Edelman; Alexandria Brackett; Craig G Gunderson Journal: J Gen Intern Med Date: 2020-09-03 Impact factor: 5.128
Authors: Mansoor M Aman; Ammar Mahmoud; Timothy Deer; Dawood Sayed; Jonathan M Hagedorn; Shane E Brogan; Vinita Singh; Amitabh Gulati; Natalie Strand; Jacqueline Weisbein; Johnathan H Goree; Fangfang Xing; Ali Valimahomed; Daniel J Pak; Antonios El Helou; Priyanka Ghosh; Krishna Shah; Vishal Patel; Alexander Escobar; Keith Schmidt; Jay Shah; Vishal Varshney; William Rosenberg; Sanjeet Narang Journal: J Pain Res Date: 2021-07-16 Impact factor: 3.133
Authors: Giuliano Lo Bianco; Alfonso Papa; Michael E Schatman; Andrea Tinnirello; Gaetano Terranova; Matteo Luigi Giuseppe Leoni; Hannah Shapiro; Sebastiano Mercadante Journal: J Clin Med Date: 2021-05-25 Impact factor: 4.241